For research and educational purposes only. Not medical advice.
Cagrilintide Reference
Educational, not medical advice reference for Cagrilintide: Metabolic, Fat Loss; regulatory status, evidence posture, source review, and schedul…
Reference summary
Lau 2021 Lancet (Phase 2, n=706 adults with overweight or obesity, 26 weeks) tested once-weekly cagrilintide monotherapy at 0.3, 0.6, 1.2, 2.4, and 4.5 mg vs placebo and vs liraglutide 3 mg. The 2.4 mg cagrilintide dose reduced body weight by approximately 9.7 percent from baseline by week 26 (placebo-subtracted treatment difference up to about 7.8 percent), comparable to liraglutide. Cagrilintide is now developed primarily as the amylin component of CagriSema (Garvey 2025 NEJM REDEFINE-1 PMID 40544433; Davies 2025 NEJM REDEFINE-2 PMID 40544432).
Regulatory and posture
- Categories
- Metabolic, Fat Loss
- Aliases
- AM833, Long-acting amylin analog (monotherapy)
- Evidence posture
- human - Phase 2 monotherapy data published; the active Phase 3 development is the cagrilintide + semaglutide combination (CagriSema), not cagrilintide alone.
- Regulatory status
- Investigational as a monotherapy. Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. The pivotal Phase 3 evidence is now in the combination product CagriSema (REDEFINE-1 and REDEFINE-2 published 2025 NEJM). There is no FDA-approved cagrilintide-only drug label.
- Content review status
- investigational verified
Selected public sources
- ClinicalTrials.gov cagrilintide (long-acting amylin analog) trial search
- PubMed: Lau et al. Lancet 2021 - once-weekly cagrilintide for weight management in people with overweight and obesity (Phase 2) (PMID 34798060)
- PubMed: Garvey et al. N Engl J Med 2025 - coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE-1, Phase 3) (PMID 40544433)
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
- Protocol builder overview - Public overview of the Pro protocol builder.